Decision Resources and Millennium Research Group have published a new report that finds that Roche/Genentech's Avastin is leading the way for targeted therapies to replace current cytotoxic agents as a driving force in the non-small-cell lung cancer (NSCLC) market. The report finds that oncologists perceive Avastin as a potent, yet expensive, adjuvant first-line therapy. In addition to Avastin, which is currently approved to treat non-small-cell lung cancer, emerging targeted therapies include Bristol-Myers Squibb/Merck Serono's Erbitux, Bayer Schering's Nexavar, AstraZeneca's Recentin and Zactima, and Merck Serono's immunotherapy Stimuvax. As a result of their premium pricing, these agents will significantly impact the non-small-cell lung cancer market, but will lag far behind Avastin's expected share.

According to the new report entitled Brands & Strategies: Non-Small-Cell Lung Cancer, the launch of Avastin in 2006 in the United States represents an incremental step toward improving the prognosis of non-small-cell lung cancer patients. The addition of Avastin to standard chemotherapy treatments in the United States has extended the overall survival of patients with recurrent or advanced-stage disease from a range of 8 to 10 months to a median of 12.3 months. Owing to an extensive marketing campaign, Avastin has been widely publicized for the treatment of non-small-cell lung cancer as well as its previous approval-and enormous success-for colorectal cancer, where it has shown an even greater improvement in patient survival.

At a cost of nearly $5,500 per treatment cycle, Avastin is the most expensive non-small-cell lung cancer therapy on the market-nearly twice the cost of the next most expensive drug, Eli Lilly's Alimta.

"The high price of Avastin will hinder the agent's uptake in cost-constrained markets such as the United Kingdom, Italy, and France," said Elena Rossi, analyst at Millennium Research Group. "Regulatory bodies in these regions, such as the National Institute for Health and Clinical Excellence in the United Kingdom, will likely restrict the use of these treatments for metastatic patients because of an unsatisfactory cost-benefit analysis. Nonetheless, surveyed U.S. physicians deem Avastin's high cost as merely a neutral factor, rather than a disadvantage, and Avastin's uptake thus far suggests that the U.S. market will in fact support an agent of this price in order to improve patients' survival outcomes."

About Brands & Strategies

Brands & Strategies is the first and only report series to bring together all of the competitive information elements biopharmaceutical companies need to make informed decisions about their products and best next-steps. Each report includes the following:

  -- Physician perceptions of companies and brand attributes.   -- Physician preference for sources of information.   -- Physician opinion of future strategies, messaging, and upcoming events.   -- Trend analysis of brand-specific messaging.   -- Overview of competitive landscape.   -- Pipeline analysis by company within a specific disease.   -- SWOT analysis on each brand.   -- Brand lifecycle strategy, including clinical trial competitive      analysis.   -- Brand-specific, event-driven, 5-year annualized market forecast.   -- Country-specific, event-driven market share projections by company and      brand.   -- Drug class and brand vs. generics sales by country.   -- Pricing analysis with company-specific strategy, price for all drugs      over 5 years, impact of generics.   -- Analysis of promotional spend for each product.   -- Selling strategies based on clinical trials.   -- Prevalent and diagnosed population by country.    About Millennium Research Group 

Millennium Research Group (www.MRG.net) is a leading provider of strategic information to the healthcare sector. Focused on the medical device, pharmaceutical, and biotechnology industries, the Company provides its clients with the benefits of its specialized industry expertise through published reports and customized consulting services.

About Decision Resources

Decision Resources, Inc., (www.decisionresources.com) is a world leader in healthcare market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

  For more information, contact:    Elizabeth Marshall   Decision Resources, Inc.   781-296-2563   emarshall@dresources.com 

SOURCE: Decision Resources, Inc.

CONTACT: Elizabeth Marshall of Decision Resources, Inc.,
+1-781-296-2563, emarshall@dresources.com

Ankylosing Spondylitis Drug Market Will Reach $661 Million in 2016

View Now